Auditor Flags Substantial Doubt About Vivos Therapeutics' Ability to Continue
VVOS is trading near its 52-week low of $0.129 (13% above the low) on light trading volume (0.2× avg).
Summary
Vivos Therapeutics' FY2025 and FY2024 audit reports include a going concern warning, and the company dismissed auditor Baker Tilly effective September 29, 2026. This follows a Q2 2026 10-Q that already showed a $5.5M loss, $1.8M cash, and a going concern warning. The auditor change adds governance risk, and the formal going concern language in the annual reports confirms the company's financial distress. With a market cap under $5M and stock at $0.1451, this is a material negative for a company already struggling to stay solvent.
At the time of this announcement, VVOS was trading at $0.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.13 to $3.45. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.